Small molecules to lead Leo Pharma to greatness

In 2030, Leo Pharma wants to be the world’s leading firm within medical dermatology, and the road there is firmly anchored in small molecules, which is what the company’s scientists do best. Big molecules – which will continue to play a role – will be sourced externally.

Jörg Möller joined Leo Pharma as head of global research and development a year ago, and is now leading an extensive restructuring of the company's R&D division | Photo: MAGNUS MØLLER
by ULRICH QUISTGAARD, translated by daniel pedersen

Leo Pharma has no doubts about where the road ahead is leading it. By the end of the decade, the company aims to be one of the absolute biggest international organizations within medical dermatology, and is currently going through sweeping changes to get there.

”These are very exciting times at Leo. We are in the middle of an important transformation,” says Jörg Möller, who just celebrated his first year as head of global research and development at Leo Pharma after spending 20 years at Bayer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today